

Applicants further elect alum as a species of non-oligonucleotide mucosal adjuvant.

Applicants further elect a subject at risk of developing an infectious disease as a species of subject.


Applicants further elect an antigen from an infectious virus as a species of antigen.

Applicants further elect intranasal as a species of route of administration for oligonucleotides, antigens and CpG containing plasmids.

REMARKS

In response to the Restriction Requirement, Applicants have elected Group I and specific species with traverse. The traversal is made on the grounds that a search and examination of all the pending claims would not require an undue burden of searching. Having made this election, Applicants expressly reserve the right to file one or more divisional applications on the subject matter of the nonelected claims.

Respectfully submitted,



Helen C. Lockhart, Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617) 720-3500

Docket No. C1040/7006 (HCL/MAT)

Date: March 29, 2001

x03/30/01